+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
TauRx Pharmaceuticals Ltd - logo

TauRx Pharmaceuticals Ltd. discovers and develops treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. The company's best known product, LMTX, inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. The LMTX Phase 3 clinical trial programme, conducted in over 20 countries and involving over 1,900 patients, has recently completed. TauRx Pharmaceuticals Ltd. was founded in 2002 and is based in Singapore with a research facility in Aberdeen, Scotland.

From
Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Product Thumbnail Image

Alzheimer's Disease Global Clinical Trials Review, H2, 2019

  • Clinical Trials
  • December 2019
  • 1222 pages
From
From
From
Tau Inhibitor - Pipeline Insight, 2020 - Product Thumbnail Image

Tau Inhibitor - Pipeline Insight, 2020

  • Drug Pipelines
  • July 2020
  • 60 pages
From
From
From
Alzheimer's Disease: Dynamic Market Forecast to 2026 - Product Thumbnail Image

Alzheimer's Disease: Dynamic Market Forecast to 2026

  • Report
  • October 2018
  • 52 pages
From
From
Aphasia Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Aphasia Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • October 2018
  • 51 pages
From
From
From
Loading Indicator
adroll